Status:
COMPLETED
Identifying the Anti-Blood-Clotting Compounds in Garlic
Lead Sponsor:
National Center for Complementary and Integrative Health (NCCIH)
Conditions:
Arteriosclerosis
Intracranial Arteriosclerosis
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
This study will seek to identify the compound(s) in garlic that is (are) responsible for its ability to prevent the formation of blood clots (prevent platelet aggregation) and to determine the maximal...
Detailed Description
Published studies indicate that various types of undefined garlic products display antiplatelet activity. However, the compounds responsible for this antiplatelet effect have not been identified. Acu...
Eligibility Criteria
Inclusion
- Body mass index of 19 to 30 kg/m2
- Plans to remain in the study area for the next year
- Willingness to abstain from nonsteroidal anti-inflammatory drugs (NSAID drugs for 1 week prior to each study test
- Willingness to abstain from consuming garlic and significant amounts of onion, chocolate, or purple grape juice for 3 days prior to each study test
- Willingness to participate in all study tests
Exclusion
- Pregnancy or breast-feeding
- Serious medical condition
- Allergy to garlic or wheat
- Tobacco use
- Excessive alcohol consumption
- Under psychiatric care
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2007
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00200785
Start Date
March 1 2006
End Date
September 1 2007
Last Update
January 11 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Silliker, Inc./Plant Bioactives Research Institute
Orem, Utah, United States, 84058